PR Newswire LOS ANGELES, Sept. 12, 2024 Individuals vaccinated at these events will receive a $20 grocery gift card, while supplies last LOS ANGELES, Sept. 12, 2024 /PRNewswire/ -- L.A. Care Health Plan and Blue Shield of California ...
PR Newswire BOSTON, Sept. 11, 2024 Considering the major societal disruptions brought on by government mandates responding to the COVID19 pandemic, all communities owe their residents an objective review of the mandates imposed. BOSTON, ...
PR Newswire SEOUL, South Korea, Sept. 11, 2024 SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the current state of antiviral treatments at the "Disease ...
PR Newswire CUPERTINO, Calif., Sept. 10, 2024 CUPERTINO, Calif., Sept. 10, 2024 /PRNewswire/ -- Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical ...
PR Newswire BOSTON, Sept. 10, 2024 CMV is known to be present in semen of HIV-infected men, factors leading to shedding of each virus are unknown. Studies determining the efficacy of adding anti-CMV treatment strategies to HAART on lowering ...
PR Newswire SAN ANTONIO, Sept. 5, 2024 Antibody SC27 developed in part by Associate Professor based at Texas Biomedical Research Institute SAN ANTONIO, Sept. 5, 2024 /PRNewswire/ -- A discovery led in part by a Texas Biomedical Research ...
PR Newswire SEATTLE, Sept. 5, 2024 InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...
PR Newswire NEW YORK, Sept. 4, 2024 – Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID ...
PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Sept. 3, 2024 Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and ...
PR Newswire GAITHERSBURG, Md., Aug. 30, 2024 GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 ...
Long COVID is draining the economy by billions every year, as workers battle persistent symptoms and face challenges returning to their jobs, reports a new study led by UCL researchers. ...
A new clinical study reveals that an inhibitor of Fas ligand (FasL), also known as CD95 ligand (CD95L), could be the latest game-changing treatment for COVID-19....
Researchers are utilizing AI to detect long COVID symptoms, monitor their progression, and rule out other potential causes. This innovative approach suggests that a substantial 22.8% of the population may be affected by long-term COVID-19 ...
A study led by researchers from the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the Barcelona Institute for Global Health (ISGlobal) explores public trust in COVID-19 vaccine science and its influence on vaccine acceptance ...
A new study reveals a concerning link between COVID-19 and dyslipidemia. The pandemic led to a 29% increase in dyslipidemia risk, especially among seniors and people with type 2 diabetes. This condition, characterized by abnormal blood lipid levels, significantly elevates the risk of heart attack and stroke. ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers